5300-03-8
基本信息
异维A酸杂质4
9-顺式维甲酸
9-顺式视黄酸
9-CIS维甲酸
维A酸EP杂质D
9-顺式视黄醇酸
异维A酸EP杂质D
异维甲酸EP杂质D
9-顺-视黄酸 [干冰运输,需加收额外费用]
物理化学性质
| 熔点 | 189-191°C |
| 沸点 | 462.8±14.0 °C(Predicted) |
| 密度 | 1.011±0.06 g/cm3(Predicted) |
| RTECS号 | VH6450000 |
| 储存条件 | −20°C |
| 溶解度 | 可溶于乙腈（非常轻微）、氯仿（轻微）、DMSO（轻微）、乙醇 |
| 酸度系数(pKa) | 4.73±0.33(Predicted) |
| 形态 | 淡黄色至橙色结晶性粉末。 |
| 颜色 | 淡黄色至黄色 |
| 生物来源 | natural |
| 水溶解性 | Soluble in chloroform (50 mg/ml), DMSO (~25 mg/ml), ethanol (25 mg/ml), and acetone (25 mg/ml). Insoluble in water. |
| 敏感性 | Moisture & Light Sensitive |
| 稳定性 | Store Dry in Freezer at -20°C for up to 1 year; in Solution at -20°C for up to 3 Months. |
| InChI | InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+ |
| InChIKey | SHGAZHPCJJPHSC-ZVCIMWCZSA-N |
| SMILES | C(O)(=O)/C=C(/C=C/C=C(\C=C\C1C(C)(C)CCCC=1C)/C)\C |
| CAS 数据库 | 5300-03-8(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H315-H319-H335-H360 |
| 防范说明 | P201-P302+P352-P305+P351+P338-P308+P313 |
| 危险品标志 | T |
| 危险类别码 | R61-R36/37/38 |
| 安全说明 | S53-S26-S36/37/39-S45 |
| WGK Germany | 3 |
| 海关编码 | 29162090 |
| 毒害物质数据 | 5300-03-8(Hazardous Substances Data) |
常见问题列表
异维A酸EP杂质D是异维A酸合成过程中产生产生的杂质，又名阿利维甲酸，是治疗皮肤病领域的重要药物，是全反式维甲酸(式II，化学名：3，7-二甲基-9-(2，6，6-三甲基环己烯-1-基)-2E，4E，6E，8E-全反式壬四烯酸)的9-顺异构体。
异维A酸EP杂质D（式I化合物）的制备：在氮气保护下，往反应瓶中加入乙醇2L、全反式维甲酸100g，搅拌，然后升温至50～55℃，加入PdCl289mg。反应1.5h后，经HPLC检测产物纯度为21％。反应液缓慢降温至0～5℃，保温180分钟，抽滤；滤液加入另一干净反应瓶中，继续降温至-10～-6℃，保温20分钟，抽滤，得到产物异维A酸EP杂质D 12.1g，总收率12.1％，HPLC纯度99.60％。以全反式维甲酸为原料，采用钯化合物催化，在普通的工业级有机溶剂中可得到阿利维甲酸。方法操作简便，成本低，条件可控，便于工业生产；经过后处理步骤后，可得到纯度99％以上的阿利维甲酸，产物收率达到12％以上，具有较高的应用价值。
9-cis-Retinoic acid (1-10 μM; 0-5 days; CA 9-22 and NA cells) treatment significantly decreases proliferation in a dose-dependent manner in CA 9-22 and NA cells.
9-cis-Retinoic acid (1 μM; 24 hours) treatment significantly increases PPARγ functional activity by >200% in CA 9-22 and NA aerodigestive cells.
9-cis-Retinoic acid treatment results in the formation of a nuclear PPARγ-RXRα heterodimer supershift complex in CA 9-22 cells.
9-cis-Retinoic acid inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma (CTCL) in a dose-dependent and time-dependent manner. 9-cis-Retinoic acid also induces G0/G1 cell cycle arrest by downregulation of cyclin D1. 9-cis-Retinoic acid significantly decreases phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1.
Cell Proliferation Assay
| Cell Line: | CA 9-22 and NA cells |
| Concentration: | 1 μM, 10 μM |
| Incubation Time: | 0 day, 1 day, 3 days, 5 days |
| Result: | Significantly decreased proliferation. |
9-cis-Retinoic acid (1 mg/kg; intravenous injection; daily; for 10 days; male C57BL/6J mice) treatment significantly decreases the serum ALT and AST level, alleviates hepatic necrosis of the bile duct ligation (BDL)-mice.
| Animal Model: | Male C57BL/6J mice (6-8 weeks; 19-22 g) treatment with bile duct ligated |
| Dosage: | 1 mg/kg |
| Administration: | Intravenous injection; daily; for 10 days |
| Result: | Significantly decreased the serum ALT and AST level, alleviated hepatic necrosis. |
知名试剂公司产品信息
9-顺式维甲酸价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-15128 | 9-顺式维甲酸 9-cis-Retinoic acid | 5300-03-8 | 1 mg | 680元 |
| 2025/05/22 | HY-15128 | 9-顺式维甲酸 9-cis-Retinoic acid | 5300-03-8 | 10 mM * 1 mLin DMSO | 991元 |
| 2025/05/22 | HY-15128 | 9-顺式维甲酸 9-cis-Retinoic acid | 5300-03-8 | 5mg | 997元 |